FDA approves 'potential blockbuster' migraine jab from Lundb...

The FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs from a new class.

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

Pfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’

First UK patients get Novartis’ Luxturna gene therapy for bl...

NICE backs Axonics’ rechargeable device for overactive bladd...

ICER methods could be illegal in US, claims US think tank